January 15th, 2026
The thymus is a small inner organ near the heart that is responsible for the maturation of T cells of the adaptive immune system. The supply of new T cells is critical to the maintenance of effective immune function over time. Unfortunately the thymus atrophies over the course of adult life, and in most people is largely made up of inactive fat tissue by as early as 50 years of age. The resulting diminished supply of replacement cells ensures that the T cell population thereafter becomes ever more made up of malfunctioning, exhausted, and senescent cells incapable of mounting an effective response.
Given the pressing need for ways to restore lost immune function in older individuals, it is good to see that a fair number of biotech startup companies are now competing to develop means of regenerating the aged thymus. After something of an abandonment of efforts following 2010s work on FOXN1 as a regulator of thymic growth, the past few years have seen a number of programs make the leap from academia to industry. Hopefully one or more will result in a form of therapy that is both effective and cost-effective.
The primary challenge presented by the thymus is targeted delivery of therapeutics. Quite a few approaches are known to kickstart the thymus into regrowth of the active regions of tissue capable of nurturing new T cells. Unfortunately they all produce serious side-effects in other tissues when delivered at sufficient high systemic doses to ensure that enough of the therapeutic make it to the thymus. For example, delivery of recombinant keratinocyte growth factor (KGF) reliably regrows the thymus in aged mice and non-human primates. There is a human drug based on KGF, used sparingly for some complications of cancer therapy. Dosing with this drug at levels sufficient to regrow the human thymus would result in very unpleasant complications, sufficiently serious to disqualify its use in this context.
